A first in human clinical trial assessing IDE034
Latest Information Update: 18 Nov 2024
Price :
$35 *
At a glance
- Drugs IDE 034 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- 18 Nov 2024 New trial record
- 11 Nov 2024 According to IDEAYA Biosciences media release, the company is targeting an IND-filing for IDE034 in 2025 to enable first-in-human clinical evaluation of B7H3/PTK7 topo-I-payload BsADC program